Anadys Rockets 115% on Hep C Data

Stock quotes in this article: ANDS , PFE , GILD , MRK  

Anadys intends to continue testing higher doses of ANA598 in the ongoing phase Ib study while it completes animal toxicity studies the company needs before starting longer combination studies of the drug in hepatitis C patients.

Anadys shares soared Thursday, ending the trading session up 114.7% to $2.19.
  • Loading Comments...
  •  
1 2
Next >

SHARE:

  • email
  • print
  • comment
  • digg
  • delicious
  • linkedin
At the time of publication, Feuerstein's Biotech Select model portfolio was long Gilead Sciences.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Recent Comments





Connect with TheStreet

Dow Jones S&P 500 NASDAQ 10-Year Note
10,309.92 1,091.49 2,138.44 32.31
Oil *
77.12
DOWN
154.48
DOWN
19.14
DOWN
37.61
DOWN
0.48
10 Yr
3.23%
SPDR Gold
115.06
-1.48%
-1.72%
-1.73%
-1.46%
Data delayed 20 minutes

Brokerage Partners

TheStreet Premium Services

All Services